We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

9999:HKEXNetease Inc Analysis

Data as of 2026-07-16 - not real-time

HK$204.60

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

NetEase trades at HK$204.6, roughly 22% below the DCF-derived fair value of HK$230.6, offering a clear valuation cushion. The company posts a robust ROE of 22% and an operating margin above 40%, underscoring strong profitability, while a 2.23% dividend yield with a 39.6% payout ratio signals sustainable cash returns. Technical signals are mixed: the price sits above the 20‑day (HK$199.35) and 50‑day (HK$192.53) SMAs, yet the MACD histogram is negative and the MACD line trails its signal, hinting at short‑term bearish pressure. Volume is on an upward trend, supporting liquidity, but the 30‑day volatility of over 35% signals heightened price swings. With a low beta around 0.5, the stock is less sensitive to market moves, though regulatory scrutiny on gaming in China and the concentration of revenue in the domestic market remain material risks.
Given the upside potential, strong cash position (HK$170.9B) versus modest debt, and positive analyst sentiment (strong‑buy consensus), the stock is positioned for upside over medium to long horizons, especially as new game releases and AI‑driven education services accelerate growth.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Undervalued price relative to DCF fair value
  • Strong cash generation and sustainable dividend
  • Technical bearish signal limited to near term

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE and operating margins driving earnings growth
  • Analyst consensus of strong‑buy and elevated target prices
  • Expansion in AI‑enabled education and international gaming

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Durable competitive moat in gaming and digital services
  • Continued dividend payout supporting shareholder returns
  • Robust balance sheet with low net leverage

Key Metrics & Analysis

Financial Health

Revenue Growth6.10%
Profit Margin29.84%
P/E Ratio16.8
ROE22.13%
ROA11.00%
Debt/Equity6.47
P/B Ratio3.4
Op. Cash FlowHK$52.4B
Free Cash FlowHK$34.1B
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI56.0
SupportHK$180.20
ResistanceHK$216.60
MA 20HK$199.35
MA 50HK$192.53
MA 200HK$202.42
MACDBearish
VolumeIncreasing
Fear & Greed Index91.55

Valuation

Fair ValueHK$230.63
Target PriceHK$249.95
Upside/Downside22.16%
GradeUndervalued
TypeBlend
Dividend Yield2.23%

Risk Assessment

Beta0.45
Volatility35.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.